



HENRY FORD HEALTH®

3rd Annual

Multidisciplinary Reviews in Malignant Hematology - Acute Leukemia

Friday, October 24, 2025

7:00 a.m. – 2:30 p.m.

Location: Westin Book Cadillac, Detroit, MI
Complimentary Parking Available

The field of Acute Leukemia (Acute Myeloid Leukemia & Acute Lymphoid Leukemia), its diagnosis, and multidisciplinary management is a constantly evolving field. Over the recent past we have witnessed how an enhanced classification system has helped us better assess disease biology and function for improved therapeutic intervention, while a deeper understanding of the underlying disease mechanisms has in turn informed us of the ways in which we can devise management strategies using traditional, targeted, immunomodulatory, and cellular therapies. This update is intended to enhance our understanding of the mechanisms behind the development and progression of acute leukemias, in particular acute myeloid and lymphoid leukemias, the ways in which they are now being treated, their resistance pathways, and the ever-increasing novel management concepts being tested in the lab and clinic. The hope is that we can come away from this conference with a better understanding of these disorders and use this knowledge to both further the field and better help in the care of our patients.

AMA PRA Category 1 Credits™ (5.00 hours), Non-Physician Attendance (5.00 hours)

Objectives

At the conclusion of this activity, learners will be able to:

- Understand the morphologic and cytogenetic evaluation of Acute Leukemia.
- Evaluate multi-modality management of newly diagnosed and relapsed Acute Leukemia.
- Assess the sequencing of T-cell directed therapy in Acute Leukemia.
- Conceptualize how newer treatment modalities might modify standards of care in the near future.

ACCREDITATION: Henry Ford Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **DESIGNATION STATEMENT:** Henry Ford Health designates this live course for a maximum of 5.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **FACULTY/PLANNING COMMITTEE DISCLOSURE STATEMENT:** In compliance with the ACCME standards for Commercial Support, all individuals in a position to control/influence the content of this activity are required to disclose all financial interests of their own with any ACCME defined commercial interests for the past 24 months and/or non-FDA approved use of a drug or a device that is included in the presentation. All financial relationships have been mitigated prior to the commencement of the activity. **ACCESSIBILITY STATEMENT:** Henry Ford Health provides qualified interpreters and other aids for Deaf, DeafBlind, and Hard-of-Hearing persons at no cost. To request assistance, contact the event coordinator: CME@hfhs.org. Please allow a minimum of 3 days to process this request. **CANCELLATION POLICY:** Please send cancellation requests to cme@hfhs.org. Henry Ford Health Office of Continuing Medical Education reserves the right to cancel or postpone this program if necessary; in the event of cancellation, course fees will be fully refunded. We are not responsible for other costs incurred such as non-refundable airline tickets or hotel penalties.



For complete information and to register, scan or visit:

<https://hfhs.cloud-cme.com/course/courseoverview?P=5&EID=86627>

3rd Annual

Multidisciplinary Reviews in Malignant Hematology - Acute Leukemia

Friday, October 24, 2025

7:00 AM-7:55 AM	Registration/Light Breakfast
7:55 AM-8:00 AM	Welcome & Housekeeping:
8:00 AM-8:30 AM	The ongoing place for intensive induction therapy in 1L AML: (Ahmad Mattour, MD)
8:30 AM-9:00 AM	Two's company but is three a crowd for less intensive induction in 1L AML? (Christopher Willner, DO)
9:00 AM-9:30 AM	Risk Stratification & Management in Pediatric AML: (Erin Goode, MD)
9:30 AM-10:00 AM	Case Discussion on RR AML: (Fellow case presentations: 1. Kim Boldig, DO/Abdel-Azez Abu Samak, MD; Discussants: Leo Reap MD, Shatha Farhan, MD, Mira Shah, MD, Sharmila Ghosh, MD, Brandon Shaw, Ph.D - Moderator: Ahmad Mattour, MD)
10:00 AM-10:15 AM	COFFEE/SNACKS
10:15 AM-10:45 AM	Pathologic, Cytogenetic and Molecular risk stratification of B-ALL: (Elizabeth Wey, MD)
10:45 AM-11:15 AM	Updates on the Treatment of Pediatric ALL: (Danielle Bell, MD)
11:15 AM-11:45 AM	CAR-T Therapy in B-cell ALL – SOC and the-not-so SOC: (Muneer Abidi, MD).
11:45 AM-12:15 PM	Case Discussions on ALL (Upfront and RR): (Fellow case presentations: Tanushree Bhatt, MD/Mohamad Bakkar, MD; Discussants: Erin Goode, MD, Edward Peres, MD, Kedar Inamdar, MD, Olena Kis, Ph.D – Moderator: Christopher Willner, DO)
12:15 PM-12:45 PM	LUNCH
12:45 PM-1:45 PM	Keynote Address – Making the Cure of AML an ever-increasing reality in 2025 (Harry Erba, MD, Duke University, Durham, NC)
1:45 PM-1:50 PM	Vote of Thanks